Search Results - "Pasta, D.J"

PRM139 Including Patients in Multiple Groups and Multiple Times in the Same Group in Longitudinal Observational Research: A Cystic Fibrosis Example by Pasta, D.J, Millar, S.J

Get full text

311 Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis by VanDevanter, D.R, Pasta, D.J, Konstan, M

“…Objectives Pulmonary exacerbations (PEx) are important clinical events and reduction of PEx risk is a useful clinical trial efficacy endpoint in CF. Methods We…”
Get full text

WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009 by VanDevanter, D.R, Pasta, D.J

Get full text

Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients by Benza, R.L, Elliott, C.G, Farber, H.W, Foreman, A.J, Frost, A.E, Gomberg-Maitland, M, McGoon, M.D, Pasta, D.J, Selej, M, Frantz, R.P

Get full text

PRM4 A MIXED-Effects Piecewise Linear Model Of The Rate Of Lung Function Decline Before And After Inhaled Corticosteroids In An Observational Study Of Children With Cystic FIBROSIS by Pasta, D.J, Rasouliyan, L

Get full text

54 Relationship between rate of percent predicted FEV1 (ppFEV1 ) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA) by Konstan, M.W, McKone, E.F, Moss, R.B, Lubarsky, B, Rubin, J, Millar, S.J, Pasta, D.J, Mayer-Hamblett, N, Goss, C.H, Morgan, W, Sawicki, G.S

Get full text

PND67 A Mixed-Effects Piecewise Linear Model of the Rate of Lung Function Decline Before and After the Clinical Use of Dornase Alfa in an Observational Study of Cystic Fibrosis by Pasta, D.J, Millar, S.J, Rasouliyan, L

Get full text

WS3.1 The effect of ivacaftor on the rate of lung function decline in CF patients with a G551D-CFTR mutation by Sawicki, G.S, McKone, E, Pasta, D.J, Wagener, J, Johnson, C, Konstan, M.W

Get full text

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint by Konstan, M.W, Wagener, J.S, Yegin, A, Millar, S.J, Pasta, D.J, VanDevanter, D.R

“…Abstract Background Rate of lung function decline (RLFD) (as FEV1 percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study…”
Get full text

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint by VanDevanter, D.R, Yegin, A, Morgan, W.J, Millar, S.J, Pasta, D.J, Konstan, M.W

“…Abstract Background Reduction in pulmonary exacerbations is an important efficacy endpoint for CF clinical studies. Powering exacerbation endpoints requires…”
Get full text

337 Changing incidence and thresholds for pulmonary exacerbation treatment, North America 1995-2005 by VanDevanter, D.R, Elkin, E.P, Pasta, D.J, Morgan, W.J, Konstan, M.W

Get full text

PND46 Longitudinal Assessment of Health-Related Quality of Life in an Observational Cohort of Patients With Cystic Fibrosis by Sawicki, G.S, Rasouliyan, L, Mcmullen, A.H, Wagener, J.S, Mccolley, S.A, Pasta, D.J, Quittner, A.L

Get full text

180 Choice of IV vs. non-IV antibiotics for treating pulmonary exacerbations in patients with cystic fibrosis by Wagener, J.S, VanDevanter, D.R, Regelmann, W, Rasouliyan, L, Morgan, W.J, Pasta, D.J, Konstan, M.W

Get full text

Early childhood wheezing is associated with lower lung function in cystic fibrosis by Ren, Clement L., Konstan, Michael W., Rosenfeld, Margaret, Pasta, David J., Millar, Stefanie J., Morgan, Wayne J.

“…Summary Objective To study the association between wheezing in children with cystic fibrosis (CF) and lung function in later life. Methods We used data from…”
Get full text

Design and powering of cystic fibrosis clinical trials using rate of FEV 1 decline as an efficacy endpoint by Konstan, M.W., Wagener, J.S., Yegin, A., Millar, S.J., Pasta, D.J., VanDevanter, D.R.

“…Rate of lung function decline (RLFD) (as FEV 1 percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part…”
Get full text

Assessing Health-Related Quality-of-Life and Health State Preference in Persons with Obesity: A Validation Study by Mathias, Susan D., Williamson, Cynthia L., Hilary H. Colwell, Cisternas, Miriam G., David J. Pasta, Bradley S. Stolshek, Patrick, Donald L.

“…The objective of this study was to assess the reliability, validity and responsiveness of a new health-related quality-of-life (HRQOL) measure containing…”
Get full text

Educational video game for juvenile diabetes: results of a controlled trial by Brown, S. J., Lieberman, D. A., Gemeny, B. A., Fan, Y. C., Wilson, D. M., Pasta, D. J.

“…Packy & Marlon®, an interactive video game designed to improve self-care among children and adolescents with diabetes, was evaluated in a six-month randomized…”
Get full text

DEMOGRAPHIC AND CLINICAL PARAMETERS ASSOCIATED WITH USE OF MEDICAL THERAPY AT ENROLMENT IN THE BPH REGISTRY AND PATIENT SURVEY by Roehrborn, C.G., Wei, J.T., Althof, S.E., Marks, L.S., Pasta, D.J., Seftel, A.D.

Get full text

Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock by Babaev, A., Frederick, P.D., Pasta, D.J., Every, N., Sichrovsky, T., Hochman, J.S.

Get full text